Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole extension for agitation in Alzheimer's dementia
NCT03594123Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2018
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brexpiprazole orally disintegrating tablet in Alzheimer's disease (AD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Oct 2018; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03594123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594123.